
In a nationwide multicenter observational study, 551 patients with solid tumours undergoing immune checkpoint inhibitor (ICI) therapy were retrospectively analyzed. Patients with pre-existing chronic coronary syndromes (CCS) or risk factors (CRF) showed significantly improved progression-free survival (PFS) and overall survival (OS) compared to those without CCS/CRF. Additionally, CCS/CRF patients exhibited higher objective response rates (ORR) and disease control rates (DCR). These findings suggest that ICIs may be more efficacious in solid tumour patients with pre-existing CCS/CRF without increased risk of severe irAEs.
Like
Save
Share